Piper Jaffray Assumes Biogen (BIIB) at Overweight
Get Alerts BIIB Hot Sheet
Price: $193.18 -0.48%
Rating Summary:
29 Buy, 13 Hold, 0 Sell
Rating Trend: Down
Today's Overall Ratings:
Up: 16 | Down: 11 | New: 13
Rating Summary:
29 Buy, 13 Hold, 0 Sell
Rating Trend: Down
Today's Overall Ratings:
Up: 16 | Down: 11 | New: 13
Join SI Premium – FREE
Piper Jaffray assumes coverage on Biogen (NASDAQ: BIIB) with a Overweight rating and a price target of $390.00.
Analyst Chris Raymond believes the company can top estimates with key growth driver Spinraza. The analyst also notes that over the LT he believes in the Alzheimer's compound aducanumab which should have Phase 3 data by YE 2019. Raymond raises his FY 2017 PES estimate slightly and lowers FY 2018 incrementally.
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $338.10 Friday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen (BIIB) PT Lowered to $270 at Oppenheimer
- Cantor Fitzgerald Starts Incyte (INCY) at Neutral, 'JAK-ing Up Its Pipeline In Advance of a Major Patent Cliff'
- Spotify (SPOT) PT Raised to $340 at Evercore ISI following strong Q1 results
Create E-mail Alert Related Categories
Analyst Comments, New CoverageRelated Entities
Piper JaffraySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!